for carcinogenicity hazard assessment
Experts in mechanistic toxicity testing
Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in the drug/compound development pipeline, thereby contributing to the development of better medicines and products and to reduce animal testing. We offer services in the following fields:
Genetic Toxicology
We have extensive experience and knowhow in the field of Genetic Toxicology. We often combine our unique ToxTracker assay with a range of extended protocols and additional assays to unravel the underlying mechanism of genotoxicity and predict the outcomes in the regulatory in vitro and in vivo genotoxicity assays.
Developmental Toxicology
By combining our expertise in stem cell technologies and reporter systems, we have generated ReproTracker, an in vitro assay that is able to visualise key processes in the early embryonic development. The assay can be applied to assess developmental toxicology in the early phases of drug development.
Mechanistic Toxicology
All assays that are developed at Toxys are aimed at understanding the mechanism underlying toxicity. We believe that this mechanistic understanding is key to translate the results from in vitro test systems to a relevance for humans. These mechanism-based test systems can be particularly useful in an Adverse Outcome Pathway (AOP) approach for both genotoxic and non-genotoxic carcinogens and in the development of an Integrated Approach to Testing and Assessment (IATA).
Happy Customers
We work together with a growing number of customers from different industries ranging from pharmaceutical companies to chemical and consumer-goods companies and from large size companies to small start-ups. We offer unique in-house screening capabilities combined with the responsiveness and flexibility found only in smaller companies. Please read what some of our customers said about working together:
"The differentiation between aneugens and clastogens is important in the hazard assessment of our pharmaceutical compounds. ToxTracker ACE conveniently combines the relevant endpoints to be able to do this"
“As a modern safety laboratory requiring mechanistic insights into mammalian toxicology, we adopted ToxTracker and installed the assay in-house. The expertise, training and support provided by Toxys for the technology transfer were excellent resulting in a seamless set-up of the assay in our facilities. In addition, we have had terrific reactivity from Giel and his team with our questions.”
"The ToxTracker assay is an excellent tool to evaluate the genotoxic potential of compounds, generating great additional value by dissecting the underlying genotoxic mechanisms, and thereby better assess the relevance of the genotoxic response in a fast and cost-efficient manner.”
“In regulatory assessment of carcinogenic or germ cell mutagenic risk, it is becoming increasingly important to understand mode of action, and not just rely on weight of negative evidence from in vivo genotoxicity studies to overrule positive in vitro genotoxicity results. To this end, there is increasing demand for integrated mechanism-based assays like ToxTracker as essential components in the development of safe and specific drugs or products.”
"Orion has worked successfully with Toxys on a couple of occasions. We are happy with the open communication which makes planning the experiments and interpreting the results easy and straightforward. The assay is excellent follow-up for our in-house micronucleus test to reveal the mode-of-action and hence validate or in-validate the borderline positive/negative dilemma."
“A succesful genotoxicity screening strategy is always dependent on the availability of mechanism of action data, as this will provide a link towards risk assessment. The Toxtracker assay is able to provide this relevant information fast and reliable so that the medicinal chemist is able to drive his chemistry plan into the safe zone.”
"Mechanism-based screening assays like the ToxTracker can make a valuable contribution to the routine safety compliance screening of our products"
“The expertise at Toxys is clear when you discuss results. The proactive team works hard to generate results within the timelines"
Toxys is featured in the local newspaper
Searching for toxic substances with fluorescent cells | The course of the Bio Science Park Toxys was featured by Leidsch Dagblad, a local newspaper, in a series which delves into the world of biotech and innovations at the Leiden Bio Science Park. Our steady growth as a company and our commitment to providing human relevant...
Toxys appoints Scientific Advisory Board
Oegstgeest, The Netherlands. November 30, 2021 - Toxys BV is a biotech company based in Leiden, The Netherlands, that provides innovative, high-fidelity in vitro toxicity screening solutions to identify carcinogenic and other hazardous properties of compounds for the pharmaceutical, chemical, cosmetics and food industry. Today,...
Genotoxicity evaluation of 2,4-D, dicamba & glyphosate alone or in combination with cell reporter assays
Check out this latest publication, “Genotoxicity evaluation of 2,4-D, dicamba and glyphosate alone or in combination with cell reporter assays for DNA damage, oxidative stress and unfolded protein response” published recently in Food and Chemical Toxicology. Researchers at Kings College in London have evaluated the carcinogenic...
ToxProfiler Webinar: Validation & applications of the ToxProfiler assay for mechanistic toxicity profiling
On the 14th of October, we hosted a webinar on the validation and applications of ToxProfiler, a quantitative high throughput screening platform with a single-cell resolution. The webinar is now available through the link below. During the webinar, our guest speaker, Dr. Romain Grall, also shared...
Toxys Newsletter September 2021
Here you can view our newsletter from September 2021 [campaign id="523f0fa92b"]...
Empirical comparison of genotoxic potency estimations: the in vitro ToxTracker versus the in vivo micronucleus assay
Check out this latest publication, “Empirical comparison of genotoxic potency estimations: the in vitro DNA-damage ToxTracker endpoints versus the in vivo micronucleus assay” published recently in Mutagenesis. In this comparative study, John Wills, Paul Rees, George Johnson and colleagues (Cambridge and Swansea Universities) used a benchmark dose (BMD)...
Toxys hosts a session at the 11th World Congress on Alternatives and Animal Use in the Life Sciences
Toxys will be hosting a session with guest speakers from Unilever and Health Canada at the The 11th World Congress on Alternatives and Animal Use in the Life Science (WC11). Applications of New Approach Methods in Genotoxicity and Developmental toxicity testing Every year, large numbers of new compounds...
Toxys Newsletter July 2021
Here you can view our newsletter from July 2021 [campaign id="d6f9160929"]...
Webinar: Applications of the ToxTracker suite in early chemical safety assessment and read-across
On the 9th of June, we hosted a webinar on the applications of the ToxTracker suite in early chemical safety assessment and read-across. The webinar is now also available through the link below. During the webinar, the ToxTracker suite was introduced and we shared updates...
Latest revision of the SCCS notes of guidance for testing of cosmetic ingredients includes ToxTracker
The latest revision of the SCCS notes of guidance for testing of cosmetic ingredients was recently published and it includes ToxTracker within the toolbox for further evaluation. The mechanistic insight provided by ToxTracker into the genotoxicity of chemicals is useful as an animal-free assessment and...
